Louis Edward Tamayo, an officer of Lexeo Therapeutics, Inc., filed a Form 144 notice of proposed sale on November 17, 2026, disclosing plans to sell 1,007 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ:LXEO.

Key Highlights

  • Proposed sale: 1,007 shares of Lexeo Therapeutics common stock, with an aggregate market value of $3,279.40, according to the filing.
  • Source of shares: The shares were acquired on November 16, 2026, via restricted stock vesting from the issuer, classified as compensation.
  • Tax-related purpose: The filing states the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
  • Prior sales: Tamayo sold 4,117 shares of common stock on August 18, 2026, for gross proceeds of $20,202.53, as reported in the three-month sales history.
  • Shares outstanding: The filing lists 82,788,599 shares of common stock outstanding at the time of the notice.
  • Broker: The proposed sale is to be executed through Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917.

Tamayo's Restricted Stock Vesting and Proposed Share Sale at Lexeo Therapeutics

According to the Form 144 filing dated November 17, 2026, Louis Edward Tamayo, identified as an officer of Lexeo Therapeutics, Inc. (NASDAQ:LXEO), intends to sell 1,007 shares of the company's common stock. The filing lists an approximate sale date of November 17, 2026, and identifies Fidelity Brokerage Services LLC as the executing broker. The aggregate market value of the shares to be sold is stated as $3,279.40.

The filing discloses that the 1,007 shares were acquired on November 16, 2026, through a restricted stock vesting transaction, with the issuer named as the person from whom the shares were acquired. The nature of payment is listed as compensation. In the remarks section, the filing notes that the "sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution," indicating the proceeds are intended at least in part to satisfy tax liabilities tied to the equity award.

In the three-month sales history required by the form, the filing reports that Tamayo sold 4,117 shares of common stock on August 18, 2026, generating gross proceeds of $20,202.53. The filing was signed by Jared Cook as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Louis E. Tamayo. Lexeo Therapeutics is headquartered at 345 Park Avenue South, Floor 6, New York, New York 10010, and carries SEC file number 001-41855.

What Was Disclosed

Lexeo Therapeutics officer Louis Edward Tamayo filed a Form 144 on November 17, 2026, proposing to sell 1,007 shares of common stock acquired through restricted stock vesting, with the stated purpose of covering a tax obligation from an equity award settlement.